IRVINE, Calif., Nov. 10, 2011 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company performing DNA-based testing services for cancer and developmental disorders, reported today that total revenues for the third quarter of 2011 increased 20% to $1.2 million from $1.0 million in the third quarter of 2010. Diagnostic services revenues during the third quarter of 2011, which comprised all of the revenues generated, increased 31% compared to diagnostic services revenues of $924,000 recognized during the third quarter of 2010. The Company performed a total of 1,157 billable diagnostic tests for 101 customers in the third quarter of 2011, compared to 967 tests for 77 customers in the third quarter of 2010. For the nine months ended September 30, 2011, diagnostic services revenues increased by 34% to $3.3 million as compared to $2.5 million for the comparable 2010 period.
